These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30781349)

  • 21. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
    McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
    J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging therapeutic targets for Gaucher disease.
    Vitner EB; Vardi A; Cox TM; Futerman AH
    Expert Opin Ther Targets; 2015 Mar; 19(3):321-34. PubMed ID: 25416676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaucher disease. Unusual presentation and mini-review.
    Rizk TM; Ariganjoye RO; Alsaeed GI
    Neurosciences (Riyadh); 2015 Jul; 20(3):271-6. PubMed ID: 26166597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant bone marrow vascularization patterns in untreated patients with Gaucher disease type 1.
    Klimkowska M; Machaczka M; Palmblad J
    Blood Cells Mol Dis; 2018 Feb; 68():54-59. PubMed ID: 27836528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sphingolipids: the nexus between Gaucher disease and insulin resistance.
    Fuller M
    Lipids Health Dis; 2010 Oct; 9():113. PubMed ID: 20937139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact.
    Zimran A; Ruchlemer R; Revel-Vilk S
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):389-394. PubMed ID: 33275748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System.
    Mucci JM; Rozenfeld P
    J Immunol Res; 2015; 2015():192761. PubMed ID: 26064996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.
    Bondar C; Ormazabal M; Crivaro A; Ferreyra-Compagnucci M; Delpino MV; Rozenfeld PA; Mucci JM
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.
    Kałużna M; Trzeciak I; Ziemnicka K; Machaczka M; Ruchała M
    Orphanet J Rare Dis; 2019 Dec; 14(1):275. PubMed ID: 31791361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model.
    Balreira A; Lacerda L; Miranda CS; Arosa FA
    Br J Haematol; 2005 Jun; 129(5):667-76. PubMed ID: 15916690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucosylceramidases and malignancies in mammals.
    Astudillo L; Therville N; Colacios C; Ségui B; Andrieu-Abadie N; Levade T
    Biochimie; 2016 Jun; 125():267-80. PubMed ID: 26582417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases.
    Osellame LD; Duchen MR
    Autophagy; 2013 Oct; 9(10):1633-5. PubMed ID: 23989665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematological manifestations and complications of Gaucher disease.
    Linari S; Castaman G
    Expert Rev Hematol; 2016 Jan; 9(1):51-8. PubMed ID: 26565753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
    Mucci JM; Suqueli García F; de Francesco PN; Ceci R; Di Genaro S; Fossati CA; Delpino MV; Rozenfeld PA
    Gene; 2013 Dec; 532(2):186-91. PubMed ID: 24076352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unusual association between Neuroblastoma and Gaucher Disease: Case report and review of the literature.
    Madeo A; Garaventa A; Sementa AR; Suffia C; Di Rocco M
    Blood Cells Mol Dis; 2018 Feb; 68():106-108. PubMed ID: 27908537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
    Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment.
    Regenboog M; Bohte AE; Akkerman EM; Stoker J; Hollak CEM
    Br J Haematol; 2017 Nov; 179(4):635-647. PubMed ID: 28905365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gaucher disease and cancer incidence: a study from the Gaucher Registry.
    Rosenbloom BE; Weinreb NJ; Zimran A; Kacena KA; Charrow J; Ward E
    Blood; 2005 Jun; 105(12):4569-72. PubMed ID: 15718419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biochemical aspects of sphingolipidosis].
    Douste-Blazy L; Thouvenot JP
    Ann Biol Clin (Paris); 1972; 30(6):623-35. PubMed ID: 4569435
    [No Abstract]   [Full Text] [Related]  

  • 40. Semaphorin 7A: A novel marker of disease activity in Gaucher disease.
    Franco M; Reihani N; Dupuis L; Collec E; Billette de Villemeur T; de Person M; Moussa F; Berger MG; Belmatoug N; Le Van Kim C
    Am J Hematol; 2020 May; 95(5):483-491. PubMed ID: 31990411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.